News · 26 weeks65-25%
2026-03-012026-08-23
Mix1590d
- Insider9(60%)
- Market3(20%)
- SEC Filings2(13%)
- Other1(7%)
Latest news
25 items- SECSEC Form 10-Q filed by ClearPoint Neuro Inc.10-Q - ClearPoint Neuro, Inc. (0001285550) (Filer)
- SECClearPoint Neuro Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)
- NEWSClearPoint Neuro Reports Second Quarter 2026 ResultsPositive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA / ACCESS Newswire / August 3, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2026.Second Quarter 2026 HighlightsReported second quarter revenue of $10.9 million, representing 18% overall growth, including the recently acquired IRRAflow Portfolio; Biologics and Drug Delivery Revenue declined 15% in the quarter, primarily due to a decrease in products shipped to biopharm
- NEWSClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SasineprocelRMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease. SOLANA BEACH, CA / ACCESS Newswire / July 31, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulated its partner Aspen Neuroscience, Inc. on receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for sasineprocel (ANPD001), Aspen's investigational autologous dopaminergic neuron cell replacement therapy for Parkinson's disease.HighlightsTh
- NEWSClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026SOLANA BEACH, CA / ACCESS Newswire / July 21, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 second quarter on Monday, August 3rd, after the market close.Investors and analysts are invited to listen to the live broadcast review of the Company's 2026 second quarter on Monday, August 3rd at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6
- INSIDERDirector Richards Timothy T. was granted 222 shares, increasing direct ownership by 0.25% to 87,544 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERDirector Fletcher R John was granted 662 shares, increasing direct ownership by 0.51% to 131,011 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERChief Business Officer Stigall L. Jeremy was granted 1,781 shares, increasing direct ownership by 2% to 110,263 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERChief Financial Officer D'Alessandro Danilo was granted 1,085 shares, increasing direct ownership by 1% to 103,769 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERCEO and President Burnett Joseph was granted 1,361 shares, increasing direct ownership by 1% to 118,203 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERCEO and President Burnett Joseph exercised 20,000 shares at a strike of $2.50 and sold $387,600 worth of shares (20,000 units at $19.38) as part of a pre-agreed trading plan (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERCEO and President Burnett Joseph exercised 60,000 shares at a strike of $2.50 and sold $1,100,463 worth of shares (61,843 units at $17.79) as part of a pre-agreed trading plan (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- PRBiotech's New Frontier: Companies Breaking Through Medicine's Toughest BarriersDENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates. NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones NeOnc (NASDAQ:NTHI) is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New Drug (IND) authorization for NEO212, the company's ora
- INSIDERDirector Richards Timothy T. exercised 500 shares at a strike of $10.00 and covered exercise/tax liability with 376 shares, increasing direct ownership by 0.14% to 87,322 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERDirector Richards Timothy T. sold $65,901 worth of shares (5,415 units at $12.17), decreasing direct ownership by 6% to 87,198 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- NEWSClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global FootprintAnnouncement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, including both focused ultrasound hardware and ClearPoint Navigation Software and Robotics SOLANA BEACH, CA / ACCESS Newswire / May 27, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced plans to enter the focused ultrasound market, and demonstrated successful intravenous delivery of tracers across the blood-brain barrier in a preclinical model using the ClearPoint prototy
- INSIDERSEC Form 4 filed by Director Johnson B Kristine4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERSEC Form 4 filed by Director Liau Linda M.4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERSEC Form 4 filed by Director Fallon Lynnette C4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERSEC Form 4 filed by Director Fletcher R John4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERDirector Klein Matthew B. sold $185,440 worth of shares (16,000 units at $11.59), decreasing direct ownership by 25% to 46,935 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERSEC Form 4 filed by Director Richards Timothy T.4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERDirector Fallon Lynnette C converted options into 12,417 shares and sold $56,714 worth of shares (5,091 units at $11.14) as part of a pre-agreed trading plan, increasing direct ownership by 18% to 48,227 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERDirector Klein Matthew B. converted options into 12,417 shares, increasing direct ownership by 25% to 62,935 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
- INSIDERDirector Richards Timothy T. converted options into 12,417 shares, increasing direct ownership by 15% to 92,613 units (SEC Form 4)4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)
CLPT FAQ
6 questionsWhat does ClearPoint Neuro Inc. do?
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally...Where does CLPT stock trade?
ClearPoint Neuro Inc. (CLPT) is listed on NASDAQ.What sector and industry is CLPT in?
ClearPoint Neuro Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about CLPT?
ClearPoint Neuro Inc. has had 5 recent analyst actions on file. The most recent action was from Stifel: Buy with a $1600.00 price target on 2026-05-08. Recent price targets range from $800.00 to $1600.00.What companies are similar to CLPT?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare CLPT side-by-side with any of them on Quantisnow.How can I track CLPT on Quantisnow?
Quantisnow aggregates ClearPoint Neuro Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLPT to receive live email and push alerts on every new disclosure.